Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Arthritis Rheum. 2008 Oct;58(10):2968-80. doi: 10.1002/art.23940.
Arthritis Rheum. 2008.
PMID: 18821691
Free article.
Clinical Trial.